{"id":"r21matrix-m","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"R21/Matrix M combines the recombinant circumsporozoite protein (CSP) antigen R21 with the Matrix M adjuvant to stimulate both cellular and humoral immune responses against malaria parasites. The vaccine targets the pre-erythrocytic stage of the parasite lifecycle, preventing parasites from reaching and infecting liver cells. Matrix M is a saponin-based adjuvant that enhances the immunogenicity of the R21 antigen.","oneSentence":"R21/Matrix M is a recombinant protein subunit malaria vaccine that elicits immune responses against the Plasmodium falciparum parasite.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:09.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria prevention in children and infants in endemic regions"}]},"trialDetails":[{"nctId":"NCT06578572","phase":"PHASE3","title":"Seasonal R21 Mass Vaccination for Malaria Elimination","status":"RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2024-05-30","conditions":"Malaria","enrollment":16200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R21Matrix M","genericName":"R21Matrix M","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Biologic","firstApprovalDate":"","aiSummary":"R21/Matrix M is a recombinant protein subunit malaria vaccine that elicits immune responses against the Plasmodium falciparum parasite. Used for Malaria prevention in children and infants in endemic regions.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}